Reading COLL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COLL free→Reading COLL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COLL free→QuarterlyIQ Insights · COLL
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2026 Inducement Plan On May 11, 2026, the Company’s board of directors adopted the Company’s 2026 Inducement Plan (the “ Inducement Plan ”), pursuant to which the Company may grant non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, and dividend equivalent rights with r…
Completion of Acquisition or Disposition of Assets. As previously disclosed, on March 19, 2026, Collegium Pharmaceutical, Inc. (the “ Company ”), entered into an Equity Purchase Agreement (the “ Purchase Agreement ”) with Corium Therapeutics Holdings, LLC, a Delaware limited liability company (“ Commave Seller ”), and Corium, LLC, a Delaware limited liability company (“ Corium Seller ” and together with Commave Seller, the “ Seller Parties ”). On May 12, 2026, pursuant to the Purchase Agreeme…
Results of Operations and Financial Condition. On May 7, 2026, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under
Departure of Directors or Principal Officers; Election of Directors Director Nominee On April 6, 2026, the board of directors (“Board”) of Collegium Pharmaceutical, Inc. (the “Company”) approved the nomination of Michael Donovan to stand for election at the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”). Mr. Donovan, 60, has served as an audit Partner at Ernst & Young LLP (“EY”) since 2002. He has held several leadership roles at EY including Office Managing Partner of E…
Regulation FD Disclosure. On March 19, 2026, the Company issued a press release announcing that the Company will acquire AZSTARYS® (the “ Press Release ”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Also, on March 19, 2026, the Company held a conference call to discuss, among other things, the announcement of the acquisition of AZSTARYS®. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The informatio…
Entry into a Material Definitive Agreement. Equity Purchase Agreement On March 19, 2026, Collegium Pharmaceutical, Inc. (the “ Company ”), entered into an Equity Purchase Agreement (the “ Purchase Agreement ”) with Corium Therapeutics Holdings, LLC, a Delaware limited liability company (“ Commave Seller ”), and Corium, LLC, a Delaware limited liability company (“ Corium Seller ” and, together with Commave Seller, the “ Seller Parties ” and each, a “ Seller Party ”). Pursuant to the Purchase A…
Results of Operations and Financial Condition. On February 26, 2026, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period and fiscal year ended December 31, 2025. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.